Risk, returns & timeframes illustration
1 min read
May 8, 2023
by
Regan Pearson

Ripping off the IPO Band-Aid 🩹

It had been all quiet on the IPO front in 2023 until Johnson & Johnson’s household division Kenvue hit the markets last week. But the journey ahead isn’t all clean and clear. Legal claims threaten to follow the household product consumer giant. Rumours are also swirling that some of China’s e-commerce heavyweights may want US IPOs. That’s assuming US legislators don’t block the way.
Risk, returns & timeframes illustration
1 min read
May 8, 2023
by
Regan Pearson

Ripping off the IPO Band-Aid 🩹

It had been all quiet on the IPO front in 2023 until Johnson & Johnson’s household division Kenvue hit the markets last week. But the journey ahead isn’t all clean and clear. Legal claims threaten to follow the household product consumer giant. Rumours are also swirling that some of China’s e-commerce heavyweights may want US IPOs. That’s assuming US legislators don’t block the way.
Table of contents
Free Getting Started Course
Take your first, or next, step to becoming a confident investor with Hatch's free online course – just 10 minutes a day, for 10 days.
Weekly news from Wall St
Subscribe to The Fry Up - your weekly sizzle of headline-grabbing share market news. Read by 60,000 Kiwis to help them take charge of their investing journey.

After a quiet start for Initial Public Offerings (IPOs) in 2023, the year could be about to catch up with a bang! 💥 Rumors are swirling on prospective monster IPOs from China’s fast-fashion app Shein, chip designer ARM, and maybe even Alibaba’s giant global online commerce business. But last week it was healthcare giant Johnson & Johnson (JNJ) that kicked things off with the listing of their Kenvue (KVUE) division.

Kenvue is the business behind bathroom basics like Band-Aid, Listerine, Neutrogena and Clean & Clear. 🧴 The kind of brands that can cover both winter flu season, and those desperate last minute Mother’s Day gifts from Chemist Warehouse!

Not only did the spin-off turn Kenvue into the world’s largest pure-play consumer health company (by revenue), the US$3.8 billion they raised more than doubled the years’ total IPO proceeds to date. For J&J however, the extra cash is likely to be a mere Band-Aid on the more than 40,000 lawsuits the company has been slapped with over claims that its talc-based powder products were contaminated with the carcinogen asbestos. 🩹Although Kenvue will inherit some of the brands, parent J&J has said it will take the fall for liabilities associated with lawsuits in USA and Canada. Still, Kenvue may not be totally in the clean and clear, saying it could be subject to legal claims from outside the USA and Canada.

Kenvue’s liberation is part of a trend of once big corporates splitting into parts. Industrial heavyweight General Electric (GE) recently split out their healthcare division into GE Healthcare (GEHC) and plans to spin off their energy and aviation units in 2024. In case that wasn’t enough to give you a headache, the Panadol in your cupboard now comes from a company called Haleon (HLN - ADR), the consumer healthcare division that popped out of pharma giant GSK (GSK – ADR) last year. Phew! 😅

Regan Pearson
Finance writer
Linkedin

We’re not financial advisors and Hatch news is for your information only. However dazzling our writing, none of it is a recommendation to invest in any of the companies or funds mentioned. If you want support before making any investment decisions, consider seeking financial advice from a licensed provider. We’ve done our best to ensure all information is current when we pushed ‘publish’ on this article. And of course, with investing, your money isn’t guaranteed to grow and there’s always a risk you might lose money.

Join the Kiwis who are hatching their tomorrow and have invested more than $1 billion with Hatch.

More recent news articles

More recent learn articles

6 min read
Nov 28, 2023

Black Friday’s record-breaking US$9.8 billion US online sales, US$70.9 billion globally

New Zealand imported Black Friday from the US, but that doesn’t mean we’re spending up large during tighter economic times. While Black Friday spending soared in the US, it seems Kiwis weren’t quite so keen to part with their hard-earned cash. So who was buying in bulk in record US Black Friday shopping?
Read more
6 min read
Nov 21, 2023

Underrated Thanksgiving stocks and hopes for a seasonal market rally

While 2023 may have felt like a bumpy ride for investors it seems that recession predictions were stymied by a buoyant American economy. Could the road ahead bring in fresh optimism echoing rallies of holidays past?
Read more
5 min read
Nov 14, 2023

Affirm shares surged 24% ahead of holidays splurge

In a world of instant gratification, is buy now pay later (BNPL) just what we do now? While BNPL providers aren't rapidly bringing on more customers and people aren’t using BNPL more, shoppers are missing more payments sinking into a debt cycle helping providers’ revenue to climb. Is this why Affirm’s stock has soared 153% this year?
Read more

More recent news articles

More recent learn articles

6 min read
Nov 28, 2023

Black Friday’s record-breaking US$9.8 billion US online sales, US$70.9 billion globally

New Zealand imported Black Friday from the US, but that doesn’t mean we’re spending up large during tighter economic times. While Black Friday spending soared in the US, it seems Kiwis weren’t quite so keen to part with their hard-earned cash. So who was buying in bulk in record US Black Friday shopping?
Read more
6 min read
Nov 21, 2023

Underrated Thanksgiving stocks and hopes for a seasonal market rally

While 2023 may have felt like a bumpy ride for investors it seems that recession predictions were stymied by a buoyant American economy. Could the road ahead bring in fresh optimism echoing rallies of holidays past?
Read more
5 min read
Nov 14, 2023

Affirm shares surged 24% ahead of holidays splurge

In a world of instant gratification, is buy now pay later (BNPL) just what we do now? While BNPL providers aren't rapidly bringing on more customers and people aren’t using BNPL more, shoppers are missing more payments sinking into a debt cycle helping providers’ revenue to climb. Is this why Affirm’s stock has soared 153% this year?
Read more